CN114380912B - 结合cd47的抗体治疗剂 - Google Patents

结合cd47的抗体治疗剂 Download PDF

Info

Publication number
CN114380912B
CN114380912B CN202210050901.6A CN202210050901A CN114380912B CN 114380912 B CN114380912 B CN 114380912B CN 202210050901 A CN202210050901 A CN 202210050901A CN 114380912 B CN114380912 B CN 114380912B
Authority
CN
China
Prior art keywords
seq
antibody
ser
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210050901.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN114380912A (zh
Inventor
B·A·斯汪森
J·D·格雷
周贺钺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Priority to CN202210050901.6A priority Critical patent/CN114380912B/zh
Publication of CN114380912A publication Critical patent/CN114380912A/zh
Application granted granted Critical
Publication of CN114380912B publication Critical patent/CN114380912B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202210050901.6A 2015-03-04 2016-03-04 结合cd47的抗体治疗剂 Active CN114380912B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210050901.6A CN114380912B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128462P 2015-03-04 2015-03-04
US62/128,462 2015-03-04
PCT/US2016/020980 WO2016141328A2 (en) 2015-03-04 2016-03-04 Antibody therapeutics that bind cd47
CN202210050901.6A CN114380912B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂
CN201680024600.9A CN107921121B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680024600.9A Division CN107921121B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂

Publications (2)

Publication Number Publication Date
CN114380912A CN114380912A (zh) 2022-04-22
CN114380912B true CN114380912B (zh) 2024-07-23

Family

ID=56848772

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210050901.6A Active CN114380912B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂
CN201680024600.9A Active CN107921121B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680024600.9A Active CN107921121B (zh) 2015-03-04 2016-03-04 结合cd47的抗体治疗剂

Country Status (11)

Country Link
US (1) US10035855B2 (enExample)
EP (1) EP3265125A4 (enExample)
JP (5) JP6643350B2 (enExample)
KR (2) KR102625835B1 (enExample)
CN (2) CN114380912B (enExample)
AR (1) AR103868A1 (enExample)
AU (2) AU2016225993B2 (enExample)
IL (2) IL254321B (enExample)
MX (1) MX385673B (enExample)
TW (3) TWI843184B (enExample)
WO (1) WO2016141328A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104298A (ko) 2016-10-20 2022-07-26 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
US11352425B2 (en) 2016-11-08 2022-06-07 Absos, Llc Anti-CD47 antibodies
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
US11286301B2 (en) 2017-02-28 2022-03-29 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of CD47 blockade
AU2018312222B2 (en) 2017-08-02 2024-11-21 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
WO2019095358A1 (zh) * 2017-11-20 2019-05-23 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
CA3083946A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3107369A1 (en) * 2018-10-31 2020-05-07 I-Mab Biopharma Us Limited Novel cd47 antibodies and methods of using same
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
WO2021113596A2 (en) 2019-12-05 2021-06-10 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CN113004406B (zh) * 2019-12-20 2022-04-26 广东菲鹏制药股份有限公司 抗cd47抗体及其应用
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2022022662A1 (zh) * 2020-07-31 2022-02-03 百奥泰生物制药股份有限公司 Cd47抗体及其应用
WO2022109227A1 (en) * 2020-11-19 2022-05-27 Icahn School Of Medicine At Mount Sinai Combined cancer therapy of b7-h3 and cd47 immune checkpoint inhbitior and methods of use
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
EP4274853A4 (en) * 2021-01-05 2024-12-04 National Institute Of Biological Sciences, Beijing BISPECIFIC ANTIBODY TARGETING GPC3 AND CD47
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN117279948A (zh) 2021-05-07 2023-12-22 益免安协公司 与cd47和pd-l1特异性结合的双特异性抗体
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117881698A (zh) * 2021-06-30 2024-04-12 创新生物有限公司 对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物
KR20240091056A (ko) 2021-10-28 2024-06-21 길리애드 사이언시즈, 인코포레이티드 피리디진-3(2h)-온 유도체
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
US12358887B2 (en) 2022-03-17 2025-07-15 Gilead Sciences, Inc. IKAROS Zinc Finger Family degraders and uses thereof
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
KR102891091B1 (ko) * 2024-05-22 2025-11-27 주식회사 이뮨온시아 항-cd47 항체를 이용한 진행성 또는 전이성 고형암의 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087248A2 (en) * 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138496B2 (en) * 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
ES2616010T3 (es) * 2010-05-14 2017-06-09 The Board Of Trustees Of The Leland Stanford Junior University Anticuerpos monoclonales humanizados y quiméricos a CD47
HRP20191500T1 (hr) * 2012-02-06 2019-11-29 Inhibrx Inc Protutijela protiv cd47 i postupci njihove upotrebe
LT2900694T (lt) * 2012-09-27 2018-11-12 Merus N.V. Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai
RU2015122228A (ru) * 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
BR112015018851A2 (pt) * 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087248A2 (en) * 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2016141328A2 (en) 2016-09-09
EP3265125A2 (en) 2018-01-10
KR102625835B1 (ko) 2024-01-17
CN107921121B (zh) 2022-02-08
KR20240007967A (ko) 2024-01-17
IL254321B (en) 2021-12-01
EP3265125A4 (en) 2018-11-07
TWI719966B (zh) 2021-03-01
TWI778518B (zh) 2022-09-21
AU2016225993A1 (en) 2017-09-28
JP2021054859A (ja) 2021-04-08
TWI843184B (zh) 2024-05-21
JP2021121635A (ja) 2021-08-26
IL287958B2 (en) 2025-12-01
JP2021054858A (ja) 2021-04-08
AU2020294159A1 (en) 2021-01-28
TW202120555A (zh) 2021-06-01
JP2018510147A (ja) 2018-04-12
CA2978594A1 (en) 2016-09-09
US10035855B2 (en) 2018-07-31
MX385673B (es) 2025-03-04
JP7105938B2 (ja) 2022-07-25
TW202248215A (zh) 2022-12-16
MX2017011329A (es) 2018-06-06
CN107921121A (zh) 2018-04-17
KR20180006369A (ko) 2018-01-17
TW201639889A (zh) 2016-11-16
CN114380912A (zh) 2022-04-22
JP2020023532A (ja) 2020-02-13
IL287958B1 (en) 2025-08-01
WO2016141328A3 (en) 2016-10-27
IL254321A0 (en) 2017-11-30
KR102850868B1 (ko) 2025-08-28
AR103868A1 (es) 2017-06-07
AU2020294159B2 (en) 2024-05-02
AU2016225993B2 (en) 2020-09-24
JP6643350B2 (ja) 2020-02-12
US20160257751A1 (en) 2016-09-08
IL287958A (en) 2022-01-01
JP7137646B2 (ja) 2022-09-14

Similar Documents

Publication Publication Date Title
JP7137646B2 (ja) Ｃｄ４７に結合する抗体医薬
US10927171B2 (en) Antibody therapeutics that bind TIM3
CN108271359B (zh) 结合ctla4的抗体治疗剂
US20210163613A1 (en) Antibody therapeutics that bind cd123
US20160326264A1 (en) Antibody therapeutics that bind psma
US20160297882A1 (en) Antibody Therapeutics That Bind CD123
CN106413752A (zh) 结合cd147的抗体疗法
CA2978594C (en) Antibody therapeutics that bind cd47
HK1253584B (zh) 与cd38结合的抗体治疗剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231228

Address after: Seoul, South Kerean

Applicant after: YUHAN Corp.

Address before: California, USA

Applicant before: Sorento Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant